Synerga Fund SA

What Synerga Fund SA does

SYNERGA.fund S.A. (formerly SILVA CAPITAL GROUP S.A.) is a Kraków, Poland-based public holding company listed on the NewConnect market of the Warsaw Stock Exchange under ticker SNG. It was originally incorporated on November 18, 2010 and listed on NewConnect on June 10, 2011. The company has undergone a strategic pivot from its earlier identity to become a biotech holding vehicle centered on the ONGENO project — an experimental autologous bone marrow stem cell therapy targeting multiple sclerosis (MS). The core scientific program is conducted under the medical leadership of Dr. n. med. W. Orłowski and is structured around a tripartite partnership: Ongeno sp. z o.o. as the IP partner, JRH ASI S.A. as the capital partner, and Dr. Orłowski providing medical/scientific direction. The company's headquarters is in Kraków, Poland, with a lean team of 1-10 employees.

The underlying technology is autologous bone marrow stem cell transfer for MS treatment, delivered via a medical experiment protocol supervised by Dr. Orłowski. The intellectual property is sourced through the Ongeno sp. z o.o. partnership rather than originating from internal R&D. There are no patents, granted IP, or published clinical data disclosed in the input. Governance is dominated by shareholder January Ciszewski, who holds 41.75% of the 27,309,990 shares outstanding (free float of 58.25%), with registered capital of 2,700,000 PLN. Tomasz Wykurz serves as CEO.

The business model is currently non-commercial. As of Q1 2026, the company reported zero revenue, a net loss of -23,788.59 PLN, total assets of 20,474.96 PLN, and negative total equity of -67,558.80 PLN. The company has articulated global commercialization ambitions for the ONGENO therapy, supported by conditional capital increase and authorized capital structures intended to fund future milestones. Until clinical validation and regulatory approval are achieved, the company has no paying customers and no recurring revenue mechanic; the primary value-creation path is contingent on outcomes of the ongoing medical experiment and subsequent commercialization of the therapy internationally.

Name

Synerga Fund SA

Legal name

SYNERGA.fund Spółka Akcyjna

Website

http://www.synergafund.com.pl

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

SYNERGA.fund S.A. is a Kraków-based NewConnect-listed biotech holding company pursuing the ONGENO project, an experimental autologous bone marrow stem cell therapy for multiple sclerosis, operated through partnerships with Ongeno sp. z o.o. (IP), JRH ASI S.A. (capital), and Dr. Orłowski (medical).

Ownership category

akta.pro rank

Product category

Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Cell therapy development
• Stem cell therapy
• Biotechnology research
• Multiple sclerosis treatment
• Clinical trial operations

Headquarters

HQ city

Krakow

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pre-revenue development stage: The company is currently in the operational stage of conducting medical experiments necessary to verify the clinical and scientific effectiveness of the innovative therapy. No revenue generated as of Q1 2026 (0 PLN net revenues). Future revenue would likely come from commercialization of the cell therapy.

Distribution channels1 record

Marketing channels1 record

Core offering

SYNERGA.fund S.A. is the commercialization and scaling partner for the ONGENO project — an innovative stem cell therapy for multiple sclerosis treatment using autologous bone marrow stem cell transfer. The company is currently in the operational stage of conducting the medical experiment necessary to verify clinical and scientific effectiveness of the therapy. The offering integrates intellectual property rights with the clinical and medical expertise of project partners.

Product overview

SYNERGA.fund S.A. is a biotechnology company focused on the development and commercialization of advanced cell therapies. The company's primary product is the ONGENO project — an innovative stem cell cell therapy for multiple sclerosis treatment using autologous bone marrow stem cell transfer. SYNERGA.fund serves as the commercialization and scaling partner responsible for global marketing of the therapy, brand awareness building, and international market expansion.

Differentiator

Problem solved

Functional benefit

Brands

• ONGENO: Innovative stem cell therapy project for the treatment of multiple sclerosis using autologous bone marrow stem cell transfer. SYNERGA.fund is responsible for global marketing, brand awareness, and scaling operations to international markets.

Products and services

• ONGENO Stem Cell Therapy Innovative stem cell therapy for multiple sclerosis (MS) using autologous bone marrow stem cell transfer. The therapy integrates intellectual property rights with clinical and medical expertise of partners (Ongeno sp. z o.o. for IP and Dr. n. med. W. Orłowski for clinical execution). Intended for multiple sclerosis patients globally upon successful clinical verification and commercialization.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core and minor.

• Ongeno sp. z o.o.coreTechnology or IntegrationIntellectual Property partner that contributes industrial property rights and proprietary copyrights to the therapies and technologies used in the medical experiment for multiple sclerosis treatment.
• Dr n. med. W. OrłowskicoreStrategic or Co-development PartnerScientific and Medical Partner responsible for the research and scientific part, development of medical procedures, and supervision of transplants in MS patients undergoing the innovative therapy.
• AUTORYZOWANI.PL P.S.A.minorImplementation/ SI/ Consulting PartnerAuthorized Adviser providing AD services to the listed company on NewConnect market, assisting with regulatory compliance and market requirements.
• Dom Maklerski BDM S.A.minorChannel Partner/ Reseller/ DistributorMarket Maker (Animator rynku) - the entity acting as market maker for SYNERGA.fund shares on the NewConnect market, providing liquidity and price stabilization.

Scale indicators6 records

Recent moves8 records

Expansion highlights4 records

Emerging players

• Cellect Biotechnology: Israel-based small-cap developing selective cell-therapy technologies. Comparable small public cell-therapy company with similar capital-markets scale and early-clinical stage profile.
• Pharmicell: Korean stem-cell therapy company that has commercialised autologous cell therapies including for indications such as MS. Comparable emerging commercial-stage peer with autologous cell-therapy experience.

Direct peers

• BrainStorm Cell Therapeutics: Clinical-stage developer of autologous cell therapies for neurodegenerative diseases, including multiple sclerosis. Closest direct peer to SYNERGA.fund's ONGENO given matching autologous modality, MS indication, and early-stage biotech profile.
• Mesoblast: Develops allogeneic and autologous cellular medicines for inflammatory and immune-mediated diseases, including MS. Comparable cell-therapy developer competing in the same disease space with a more advanced clinical pipeline.
• Athersys: Cell therapy developer (MultiStem) historically pursuing neurological indications including MS. Comparable as a small-cap public cell-therapy company with a single lead programme facing large-pharma competition.
• Pluristem Therapeutics: Develops placenta-derived cell therapies for inflammatory and neurodegenerative conditions. Comparable as a publicly listed cell-therapy company pursuing indications adjacent to MS.
• Regeneus: Australia-listed developer of stem cell and immunotherapy products for inflammatory and neurological conditions. Comparable small-cap, early-stage cell-therapy developer in adjacent indications.

Broad incumbents

• Biogen: Large pharma leader in MS disease-modifying therapies (Tysabri, Tecfidera, Avonex). Represents the dominant incumbent competition that any autologous MS cell therapy must beat on efficacy and access.
• Novartis: Markets Kesimpta (ofatumumab) and other high-efficacy MS therapies. Sets the commercial benchmark for MS treatment outcomes that ONGENO would need to exceed to gain market share.
• Teva Pharmaceutical Industries: Sells Copaxone and other MS therapies. Broad incumbent competitor defining pricing and access dynamics in the MS market SYNERGA.fund is targeting.

Market position

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/synergafund

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synerga Fund SA